A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-1）
NCT ID: NCT06930612
Last Updated: 2025-04-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
120 participants
INTERVENTIONAL
2025-05-16
2026-09-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis
NCT06372678
The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps
NCT05131464
A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps
NCT05324137
A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps
NCT06639295
A Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （CROWNS-2）
NCT05436275
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CM512 Dose 1
CM512
Administered subcutaneous injection
CM512 Dose 2
CM512
Administered subcutaneous injection
CM512 Dose 3
CM512
Administered subcutaneous injection
Placebo
Placebo
Administered subcutaneous injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CM512
Administered subcutaneous injection
Placebo
Administered subcutaneous injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Nasal Polyp Score (NPS) of ≥5 with a minimum score of 2 in each nasal cavity.
* Nasal Congestion Score of 2 or 3 at screening period, and at least 2 at baseline.
* Contraception.
Exclusion Criteria
* Vaccination with live attenuated vaccine within 30 days before randomization or during the planned study period.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Keymed Biosciences Co.Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luo Zhang
Role: PRINCIPAL_INVESTIGATOR
Beijing Tong-Ren hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Tong-Ren hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CM512-102101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.